EXVIERA

This brand name is authorized in Austria, Cyprus, Estonia, Finland, Ireland, Lithuania, Poland, Romania, Tunisia, Turkey

Active ingredients

The drug EXVIERA contains one active pharmaceutical ingredient (API):

1 Dasabuvir UNII OG6D40M62L - DASABUVIR SODIUM MONOHYDRATE

Dasabuvir is a non-nucleoside inhibitor of the HCV RNA-dependent RNA polymerase encoded by the NS5B gene, which is essential for replication of the viral genome. Co-administration of dasabuvir with ombitasvir/paritaprevir/ritonavir combines three direct-acting antiviral medicinal products with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle. Read about Dasabuvir

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
EXVIERA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AP09		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AP Antivirals for treatment of HCV infections
Discover more medicines within J05AP09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1675694
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 488509
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1075472
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100334318
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W64676001
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 16913011H
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8680656080339